Metabolic Syndrome Is tied to Poor Prognosis in Patients With Breast Cancer Receiving Neoadjuvant Therapy: Study

Retrospective analysis was done on the data of breast cancer patients who received NAT at our facility between January 2017 and December 2019. The parameters linked to MetS and pathological complete response were determined using a logistic regression model and chi-square test. Both univariate and multivariate analyses of overall survival (OS) and disease-free survival (DFS) were conducted using the Cox proportional risk model.

A total of 164 (18.0%) of the 910 patients that were included had a diagnosis of MetS, 568 (62.4%) had a stage II diagnosis, and 342 (37.5%) had a stage III diagnosis. A greater incidence rate of MetS was linked to stage III and postmenopausal status. And a decreased pCR rate was linked to MetS.

The 5-year OS and DFS of the non-MetS group were noticeably superior than the MetS group's. The non-MetS group's OS and DFS were noticeably superior to the MetS group's in premenopausal women. In postmenopausal women, there were no appreciable variations in DFS or OS between the two groups.

MetS functioned as an independent factor linked to DFS and OS in the Cox proportional risk model. In individuals with breast cancer undergoing NAT, MetS was linked to a poor outcome. Overall, the patients with MetS had far worse 5-year disease-free survival and overall survival rates than people without the condition.

Source:

Ma, Y., Zhang, J., Jiao, D., Chen, X., & Liu, Z. (2024). Metabolic Syndrome Is Associated With Poor Prognosis in Patients With Breast Cancer Receiving Neoadjuvant Therapy. In Cancer Medicine (Vol. 13, Issue 24). Wiley. https://doi.org/10.1002/cam4.70484